Summit Therapeutics Q3 Losses Widen, Directors Buy Shares Amid Valuation Concerns

Summit Therapeutics reported weaker Q3 2025 results with a wider EBITDA loss and deteriorating EPS. In contrast, several company directors have been buying shares, hinting at internal confidence. The combination of worsening losses and director share purchases shapes Summit Therapeutics' investment narrative, focusing on access to capital and clinical execution. Despite the risks, directors' buying activity supports the near-term catalyst of funding runway for Pfizer and MD Anderson trials.